NCT02594839View on ClinicalTrials.gov

Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Idiopathic Interstitial PneumoniaInterstitial Lung DiseaseIdiopathic Pulmonary Fibrosis

Interventions

DRUG

Bone marrow mesenchymal stem cells

Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline

DRUG

Placebo

intravenous infusion of 400 mL saline

Trial Locations (1)

115682

Federal Research Clinical Center FMBA of Russia, Moscow

All Listed Sponsors

lead

Federal Research Clinical Center of Federal Medical & Biological Agency, Russia

OTHER_GOV

NCT02594839 - Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | Biotech Hunter | Biotech Hunter